![]() |
![]() |
![]() |
![]() |
|
Management of Metabolic Co-Morbidities
|
||
NO, O2- and renal Na handling
|
Management of Chronic Hyperkalemia
|
||
  Use of RAAS Inhibitors for Cardio-Renal Risk Reduction and Potassium Management
|
Baroreflex Activation Therapy in Patients with Resistant Hypertension
|
||
True Resistant Hypertension
|
||
Renal Denervation: How to Evaluate and Choose the Appropriate Patient
|
||
Renal Nerve Ablation
|
Off-Target Cardiovascular Effects of Non-Cardiovascular Drugs: Non-steroidal drugs
|
||
PPAR Agents
|
||
Anti-VEGF and Other Chemotherapeutic Agents
|
||
PDE5 Inhibitors and Organic Nitrates
|
Cardiovascular Risk Assessment – Addition of CKD and Race to the Framingham Equation
|
||
The Mechanisms and Treatment of Intradialytic Hypertension (MATCH) Study
|
||
Hypertension in Advanced Kidney Disease
|
||
Hypertension in Renal Transplant Patients
|
Plasma Aldosterone Levels Affect Calcium Metabolism in Patients with Essential Hypertension
|
||
Interactions Between Aldosterone and Nitric Oxide
|
||
Non-Renal Effects of Aldosterone
|
||
Inappropriately Intense Salt Restriction Augmenting Myocardial Fibrosis in Animal Model
|
Peri-operative Management of the Hospitalized Patient with Hypertension
|
||
Out of Office Monitoring to Rule Out Resistant Hypertension and Adolescents and Adolescents
|
||
Outpatient Evaluation for Secondary Causes of Resistant Hypertension
|
Acetyl-Ser-Asp-Lys-Pro, an Endogenous Tetrapeptide: Role in Target Organ Damage in Hypertension, and Autoimmune Myocarditis
|
||
Water Immersion: A Model of Volume Expansion for Assessing Renin-Aldosterone Responsiveness and Renal Sodium Handling in Humans and Adolescents
|
||
Pathological Cardiac Remodeling: Meddling with Mechanisms
|
Keynote Lecture: Blood Pressure in Obesity
|
||
Cardiovascular Risk and Risk Reduction in Children and Adolescents
|
||
Evaluation and Treatment of Hypertension in Childhood
|
![]() |
|